This report was first published by Endpoints News. To see the original version, click here
Despite all the noise around massive upcoming IPOs for AI giants, a drug developer was able to attract enough investor interest to achieve the biggest Nasdaq debut the biopharma industry has ever seen.
On Tuesday evening, Parabilis Medicines said it would sell 33.5 million shares at $20 apiece, for a total of $670 million. It will raise another $75 million in a private stock sale to its new partner Regeneron Pharmaceuticals.
您已阅读21%（518字），剩余79%（1918字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。